logo
Twitter
Discord
Email
logo
Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited

NYSE•TEVA
CEO: Mr. Richard D. Francis
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Listing Date: 1982-02-16
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.
Contact Information
124 Dvora HaNevi’a Street, Tel Aviv, 6944020, Israel
972-3-914-8213
www.tevapharm.com
Market Cap
$37.60B
P/E (TTM)
-240.8
93.6
Dividend Yield
--
52W High
$33.42
52W Low
$12.47
52W Range
97%
Rank53Top 76.1%
2.8
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.8 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q3 2025 Data

Revenue

$4.48B+3.42%
4-Quarter Trend

EPS

$0.38-197.44%
4-Quarter Trend

FCF

$233.00M-57.25%
4-Quarter Trend

2025 Q3 Earnings Highlights

Key Highlights

Net Income Reverses Loss Net income attributable to Teva $433M in Q3 2025, reversing prior period net loss of $(437)M.
US Profit Jumps 25% US segment profit $937M, up 25% versus Q3 2024, driven by AUSTEDO revenue growth.
Gross Margin Expansion Q3 Gross profit margin improved to 51.4% from 49.6% last year, reflecting favorable product mix.
Operating Income Swing Operating income $882M in Q3 2025, a major swing from $51M operating loss in Q3 2024.

Risk Factors

Ongoing Legal Contingencies Provision for legal settlements $60M in Q3 2025; opioid/antitrust litigation remains material exposure.
API Divestiture Uncertainty Strategic intention to divest API business continues, but ultimate timing or completion is not assured.
Significant Debt Load Significant indebtedness may limit ability to incur additional debt or make new strategic investments.
Currency Fluctuation Impact Approximately 41% of Q3 revenues denominated in non-USD currencies, creating foreign exchange risk exposure.

Outlook

Accelerate Growth Strategy Executing second phase of Pivot to Growth strategy, focusing capital allocation on high-value innovative portfolio.
Workforce Transformation Plan Transformation programs announced May 2025 target 8% workforce reduction by end of 2027 for cost savings.
Innovative Pipeline Advancement DARI (ICS/SABA) and duvakitug (anti-TL1A) both advanced to Phase 3 clinical trials.
Liquidity Position Strong Expects sufficient cash resources to support all debt service payments and financial obligations within one year.

Peer Comparison

Revenue (TTM)

Genmab A/SGMAB
$18.26B
-7.6%
Teva Pharmaceutical Industries LimitedTEVA
$16.78B
-0.0%
Labcorp Holdings Inc.LH
$13.77B
+8.3%

Gross Margin (Latest Quarter)

Neurocrine Biosciences, Inc.NBIX
98.2%
-0.5pp
Genmab A/SGMAB
94.3%
-0.7pp
BioNTech SEBNTX
90.2%
+4.6pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
TEVA$37.60B-240.8-2.6%42.9%
NTRA$32.50B-104.5-25.1%10.1%
BIIB$27.23B16.99.3%22.6%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
1.9%
Moderate Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
75%
Volatile Cash Flow

Research & Insights

Next earnings:Jan 28, 2026
|
EPS:$0.64
|
Revenue:$4.33B
Reports
All Years
  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 5, 2025|
    Revenue: $4.48B+3.4%
    |
    EPS: $0.38-197.4%
    Miss
  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Jul 30, 2025|
    Revenue: $4.18B+0.3%
    |
    EPS: $0.25-133.3%
    Miss
  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 7, 2025|
    Revenue: $3.89B+1.5%
    |
    EPS: $0.19-258.3%
    Miss
  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 5, 2025|
    Revenue: $16.54B+4.4%
    |
    EPS: $-1.45-190.0%
    Miss
  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 6, 2024|
    Revenue: $4.33B+12.5%
    |
    EPS: $-0.39-646.2%
    Miss
  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Jul 31, 2024|
    Revenue: $4.16B+7.3%
    |
    EPS: $-0.75-2.6%
    Miss
  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 8, 2024|
    Revenue: $3.83B+4.6%
    |
    EPS: $-0.12-40.0%
    Miss
  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 12, 2024|
    Revenue: $15.85B+6.2%
    |
    EPS: $-0.50+77.3%
    Miss